STAT+: Psilocybin data could be good enough for approval

The FDA has refused to review Moderna's application for its mRNA influenza vaccine, marking a significant setback for the Cambridge biotech firm. This decision raises concerns regarding the agency's overall approach to vaccine and drug approvals. The refusal to review the application has been characterized as a blow to Moderna, which has been at the forefront of mRNA technology, particularly during the COVID-19 pandemic. The FDA's decision comes amid ongoing scrutiny of vaccine approvals and the regulatory processes involved. Vinay Prasad, a key figure in the FDA's decision-making, has reportedly overruled career FDA scientists in rejecting Moderna's flu vaccine application. This action reflects a trend of placing vaccines under more stringent scrutiny than in previous years. The implications of this decision could extend beyond Moderna, potentially affecting the broader landscape of vaccine development and approval processes within the FDA. The refusal to review the application has sparked discussions among pediatricians and other healthcare professionals regarding the agency's stance on vaccines. As the FDA navigates these challenges, the outcomes of such decisions may influence public trust in vaccine safety and efficacy, particularly as new vaccines are developed and submitted for approval. The situation remains dynamic, with stakeholders closely monitoring the FDA's future actions and policies regarding vaccine approvals.